The closed sites include some that came with its $1.25 billion takeover of CureVac last year, and BioNTech has said it hopes ...

It is the second licensing deal involving siRNA between GSK and a Chinese biotech in the last few months, coming after the UK ...

Bayer has agreed terms for its first biopharma acquisition in years, paying $300 million upfront for privately-held US ...

While still making up a modest part of that total, oral Wegovy (semaglutide) performed better than expected since its launch ...

Navdeep "Navi" Chadha is co-founder and CTO of Axtria, a global provider of AI-powered data analytics and cloud software for ...

The team, led by scientists at VIB and KU Leuven in Belgium, have identified two types of Parkinson's – and five subtypes – ...

Cytokinetics' cardiac myosin inhibitor Myqorzo has succeeded where first-to-market Camzyos from Bristol Myers Squibb failed, ...

In today’s episode of the pharmaphorum podcast, host Jonah Comstock speaks with Boyang Wang, the founder of Immortal Dragons, ...

Europe is undergoing profound social, political, and technological transformation, with direct implications for mental health ...

Autolus has picked up its first product approval, getting an FDA green light for Aucatzyl as a treatment for patients with aggressive blood cancer acute lymphoblastic leukaemia (ALL). The US regulator ...

The final ICH E6 (R3) Good Clinical Practice (GCP) Guidelines were published on 6 th January 2025, updating the framework for clinical trials to reflect modern trial designs, technology, and data ...

Novartis has signed its second licensing deal with Monte Rosa Therapeutics in less than a year, suggesting it is impressed with the US biotech's molecular glue degrader (MGD) platform. The latest ...